Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro mechanistic and cell culture study.
PubMed 26145173 · doi:10.1016/j.molcel.2015.05.037
What was done
The authors investigated the functional and metabolic relationship between oncogenic BRAF V600E and the ketogenic enzyme 3-hydroxy-3-methylglutaryl-CoA lyase (HMGCL). They assessed HMGCL expression in BRAF V600E-expressing human primary melanoma and hairy cell leukemia cells, tested the effect of HMGCL knockdown on melanoma cell proliferation and tumor growth potential, and characterized the downstream molecular pathway involving Oct-1 transcription factor, acetoacetate levels, and BRAF-MEK1 binding.
What was found
No quantitative values, effect sizes, or statistical metrics were reported in the abstract. Qualitatively, HMGCL was upregulated in BRAF V600E-positive primary melanoma and hairy cell leukemia cells, and suppressing HMGCL attenuated cell proliferation and tumor growth potential. Mechanistically, active BRAF induced HMGCL via Oct-1, increasing acetoacetate production, which selectively promoted BRAF V600E (but not wild-type BRAF) binding to MEK1 and activated MEK-ERK signaling.
Why it matters
This study establishes an oncogene-specific metabolic feedback loop linking ketogenesis directly to BRAF V600E oncogenic signaling, highlighting HMGCL and acetoacetate production as potential synthetic lethal targets in BRAF-mutant cancers.
Limits
The abstract does not disclose sample sizes, quantitative measurements, or variance estimates. The study relies entirely on in vitro preclinical cancer models and mechanistic assays, without in vivo human clinical trial data.
Cited by
- context Melanoma cell lines harboring the BRAF V600E mutation can use acetoacetate as an energy source and for biosynthetic reactions.